An inducible RIPK3-driven necroptotic system enhances cancer cell-based immunotherapy and ensures safety

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Cancer cell-based therapies show promise but face safety challenges with live cells.
• Current safety switches can induce immunosuppression, hindering immunotherapy efficacy.
• There is a need for safety switches that enhance, not impede, anti-cancer immunity.

Purpose of the Study:

• To develop and characterize a novel inducible receptor-interacting protein kinase 3 (RIPK3)-driven necroptotic system.
• To evaluate its dual function as a safety switch and an inducer of immunogenic cell death.
• To assess its impact on tumor growth, survival, and the tumor immune microenvironment (TIME).

Main Methods:

• Development of an inducible RIPK3-driven necroptotic system.
• Activation of the RIPK3 safety switch in a preclinical cancer model.
• Assessment of cell death pathways, release of ATP and damage-associated molecular patterns (DAMPs).
• Evaluation of tumor growth, survival rates, and immune cell populations within the TIME.

Main Results:

• Activation of the RIPK3 system triggered immunogenic cell death with increased ATP and DAMPs release.
• The RIPK3 system significantly inhibited tumor growth and improved survival in mice compared to existing switches.
• The system promoted dendritic cell maturation, M1 macrophage polarization, and reduced T cell exhaustion, reinvigorating the TIME.

Conclusions:

• The RIPK3-driven necroptotic system acts as a dual-function safety switch and immunogenic cell death inducer.
• This system enhances the safety and efficacy of cancer cell-based therapies.
• It offers a promising strategy for improving cellular therapies and fostering long-term antitumor immunity.